CoChat

Direct inhibition of RAS: Quest for the Holy Grail?

Open access
Spencer-Smith, Russell, O’Bryan, John P. · 2019 · Seminars in Cancer Biology
Cited by 86

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein family in human cancer. However, the relatively smooth surface architecture of RAS and its picomolar affinity for nucleotide have given rise to the assumption that RAS is an “undruggable” target. Recent advancements in drug screening, molecular modeling, and a greater understanding of RAS function have led to a resurgence in efforts to pharmacologically target this challenging foe. This review focuses on the state of the art of RAS inhibition, the approaches taken to achieve this goal, and the challenges of translating these discoveries into viable therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2017.12.005

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 85

  1. Harvey, 1964, An unidentified virus which causes the rapid production of tumours in mice, Nature, 204, 1104, 10.1038/2041104b0 · DOI · Paper page
  2. Kirsten, 1967, Morphologic responses to a murine erythroblastosis virus, J. Natl. Cancer Inst., 39, 311
  3. Hall, 1983, Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1, Nature, 303, 396, 10.1038/303396a0 · DOI · Paper page
  4. Shimizu, 1983, Three human transforming genes are related to the viral ras oncogenes, Proc. Natl. Acad. Sci. U. S. A., 80, 2112, 10.1073/pnas.80.8.2112 · DOI · Paper page
  5. Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
  6. Hall, 2002, The structural basis for the transition from Ras-GTP to Ras-GDP, Proc. Natl. Acad. Sci. U. S. A., 99, 12138, 10.1073/pnas.192453199 · DOI · Paper page
  7. Milburn, 1990, Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins, Science, 247, 939, 10.1126/science.2406906 · DOI · Paper page
  8. Zhou, 2015, Ras nanoclusters: versatile lipid-based signaling platforms, Biochim. Biophys. Acta, 1853, 841, 10.1016/j.bbamcr.2014.09.008 · DOI · Paper page
  9. Parker, 2015, The ras-membrane interface: isoform-specific differences in the catalytic domain, Mol. Cancer Res., 13, 595, 10.1158/1541-7786.MCR-14-0535 · DOI · Paper page
  10. Abankwa, 2010, Ras membrane orientation and nanodomain localization generate isoform diversity, Proc. Natl. Acad. Sci. U. S. A., 107, 1130, 10.1073/pnas.0903907107 · DOI · Paper page
  11. Abankwa, 2008, A novel switch region regulates H-ras membrane orientation and signal output, EMBO J., 27, 727, 10.1038/emboj.2008.10 · DOI · Paper page
  12. Thapar, 2004, NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation, J. Mol. Biol., 343, 1391, 10.1016/j.jmb.2004.08.106 · DOI
  13. Dharmaiah, 2016, Structural basis of recognition of farnesylated and methylated KRAS4b by PDEdelta, Proc. Natl. Acad. Sci. U. S. A., 113, E6766, 10.1073/pnas.1615316113 · DOI · Paper page
  14. Hancock, 1989, All ras proteins are polyisoprenylated but only some are palmitoylated, Cell, 57, 1167, 10.1016/0092-8674(89)90054-8 · DOI · Paper page
  15. Choy, 1999, Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi, Cell, 98, 69, 10.1016/S0092-8674(00)80607-8 · DOI · Paper page
  16. Hancock, 1990, A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane, Cell, 63, 133, 10.1016/0092-8674(90)90294-O · DOI · Paper page
  17. Hancock, 1991, A caax or a caal motif and a 2nd signal are sufficient for plasma-membrane targeting of ras proteins, EMBO J., 10, 4033, 10.1002/j.1460-2075.1991.tb04979.x · DOI · Paper page
  18. Malliri, 2002, Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours, Nature, 417, 867, 10.1038/nature00848 · DOI · Paper page
  19. Bai, 2004, Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development, Cancer Res., 64, 8808, 10.1158/0008-5472.CAN-04-3143 · DOI · Paper page
  20. Gonzalez-Garcia, 2005, RaIGDS is required for tumor formation in a model of skin carcinoigenesis, Cancer Cell, 7, 219, 10.1016/j.ccr.2005.01.029 · DOI · Paper page
  21. Castellano, 2011, Functional specificity of ras isoforms: so similar but so different, Genes Cancer, 2, 216, 10.1177/1947601911408081 · DOI · Paper page
  22. Wennerberg, 2005, The Ras superfamily at a glance, J. Cell Sci., 118, 843, 10.1242/jcs.01660 · DOI · Paper page
  23. Furth, 1982, Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family, J. Virol., 43, 294, 10.1128/JVI.43.1.294-304.1982 · DOI · Paper page
  24. Lacal, 1986, Monoclonal-Antibody Y13-259 recognizes an epitope of the P21 ras molecule not directly involved in the Gtp-binding activity of the protein, Mol. Cell. Biol., 6, 1002, 10.1128/MCB.6.4.1002 · DOI
  25. Mulcahy, 1985, Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells, Nature (London), 313, 241, 10.1038/313241a0 · DOI · Paper page
  26. Cardinale, 1998, The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells, FEBS Lett., 439, 197, 10.1016/S0014-5793(98)01369-6 · DOI
  27. Shin, 2017, Antibody targeting intracellular oncogenic ras mutants exerts anti-tumour effects after systemic administration, Nat. Commun., 8, 15090, 10.1038/ncomms15090 · DOI
  28. Clark, 1985, Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding, Proc. Natl. Acad. Sci. U. S. A., 82, 5280, 10.1073/pnas.82.16.5280 · DOI · Paper page
  29. Feramisco, 1985, Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein, Nature, 314, 639, 10.1038/314639a0 · DOI
  30. Wong, 2012, A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3K-C2b) regulation, PLoS One, 7, e45360, 10.1371/journal.pone.0045360 · DOI
  31. Pai, 1989, Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation, Nature, 341, 209, 10.1038/341209a0 · DOI · Paper page
  32. Reiss, 1990, Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides, Cell, 62, 81, 10.1016/0092-8674(90)90242-7 · DOI · Paper page
  33. Lerner, 1995, Disruption of oncogenic K-Ras4b processing and signaling by a potent geranylgeranyltransferase-I inhibitor, J. Biol. Chem., 270, 26770, 10.1074/jbc.270.45.26770 · DOI · Paper page
  34. Whyte, 1997, K- N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 · DOI · Paper page
  35. Novotny, 2017, Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K-Ras, ACS Chem. Biol., 12, 1956, 10.1021/acschembio.7b00374 · DOI · Paper page
  36. Rocks, 2005, An acylation cycle regulates localization and activity of palmitoylated ras isoforms, Science, 307, 1746, 10.1126/science.1105654 · DOI · Paper page
  37. Rocks, 2010, The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins, Cell, 141, 458, 10.1016/j.cell.2010.04.007 · DOI · Paper page
  38. Papke, 2016, Identification of pyrazolopyridazinones as PDEd inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
  39. Martin-Gago, 2017, A PDE6delta-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2, Angew. Chem. Int. Ed. Engl., 56, 2423, 10.1002/anie.201610957 · DOI · Paper page
  40. Thompson, 2013, US National Cancer Institute's new Ras project targets an old foe, Nat. Med., 19, 949, 10.1038/nm0813-949 · DOI
  41. Ahmadian, 1999, Guanosine triphosphatase stimulation of oncogenic Ras mutants, Proc. Natl. Acad. Sci. U. S. A., 96, 7065, 10.1073/pnas.96.12.7065 · DOI · Paper page
  42. Patgiri, 2011, An orthosteric inhibitor of the Ras-Sos interaction, Nat. Chem. Biol., 7, 585, 10.1038/nchembio.612 · DOI · Paper page
  43. Leshchiner, 2015, Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices, Proc. Natl. Acad. Sci. U. S. A., 112, 1761, 10.1073/pnas.1413185112 · DOI · Paper page
  44. Wu, 2013, Inhibition of ras-effector interaction by cyclic peptides, Medchemcomm, 4, 378, 10.1039/C2MD20329D · DOI · Paper page
  45. Upadhyaya, 2015, Inhibition of ras signaling by blocking ras-effector interactions with cyclic peptides, Angew. Chem. Int. Ed. Engl., 54, 7602, 10.1002/anie.201502763 · DOI · Paper page
  46. Upadhyaya, 2016, Direct inhibitors of ras-effector protein interactions, Mini Rev. Med. Chem., 16, 376, 10.2174/1389557515666151001141713 · DOI
  47. Welsch, 2017, Multivalent small-molecule Pan-RAS inhibitors, Cell, 168, 878, 10.1016/j.cell.2017.02.006 · DOI · Paper page
  48. Forbes, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res., 43, D805, 10.1093/nar/gku1075 · DOI · Paper page
  49. Zhang, 2009, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer, 9, 28, 10.1038/nrc2559 · DOI · Paper page
  50. Feuerstein, 1987, Preparation and characterization of nucleotide-free and metal ion-free p21 apoprotein, J. Biol. Chem., 262, 8455, 10.1016/S0021-9258(18)47433-9 · DOI · Paper page
  51. Finkel, 1984, Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21, Cell, 37, 151, 10.1016/0092-8674(84)90310-6 · DOI
  52. Hattori, 1985, Biochemical-properties of a highly purified V-Rash P21 protein overproduced in Escherichia-Coli and inhibition of its activities by a monoclonal-antibody, Mol. Cell. Biol., 5, 1449, 10.1128/MCB.5.6.1449 · doi:10.1128/mcb.5.6.1449
  53. Wolin, 1996, Synthesis and evaluation of pyrazolo [3,4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic ras, Bioorg. Med. Chem. Lett., 6, 195, 10.1016/0960-894X(95)00574-D · doi:10.1016/0960-894x(95)00574-d
  54. Noonan, 1991, Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins, J. Med. Chem., 34, 1302, 10.1021/jm00108a010 · DOI
  55. Taveras, 1997, Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex, Bioorg. Med. Chem., 5, 125, 10.1016/S0968-0896(96)00202-7 · DOI
  56. Peri, 2005, Design, synthesis and biological evaluation of sugar-derived Ras inhibitors, Chembiochem, 6, 1839, 10.1002/cbic.200400420 · DOI · Paper page
  57. Muller, 2017, Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity, Sci. Rep., 7, 3687, 10.1038/s41598-017-03973-6 · DOI
  58. Tanaka, 2003, Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies, J. Mol. Biol., 331, 1109, 10.1016/S0022-2836(03)00836-2 · DOI
  59. Tanaka, 2010, Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth, Oncogene, 29, 6064, 10.1038/onc.2010.346 · DOI
  60. Tanaka, 2007, Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS, EMBO J., 26, 3250, 10.1038/sj.emboj.7601744 · DOI
  61. Choi, 2014, A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells, MAbs, 6, 1402, 10.4161/mabs.36389 · DOI
  62. Kim, 2015, Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay, Biochem. Biophys. Res. Commun., 467, 771, 10.1016/j.bbrc.2015.10.066 · DOI
  63. Guillard, 2017, Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange, Nat. Commun., 8, 16111, 10.1038/ncomms16111 · DOI · Paper page
  64. Santos, 2014, Dimerization opens new avenues into Ras signaling research, Sci. Signal., 7, pe12, 10.1126/scisignal.2005318 · DOI
  65. Guldenhaupt, 2012, N-Ras forms dimers at POPC membranes, Biophys. J ., 103, 1585, 10.1016/j.bpj.2012.08.043 · DOI
  66. Lin, 2014, H-Ras forms dimers on membrane surfaces via a protein–protein interface, Proc. Natl. Acad. Sci. U. S. A., 111, 2996, 10.1073/pnas.1321155111 · DOI · Paper page
  67. Plowman, 2005, H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton, Proc. Natl. Acad. Sci. U. S. A., 102, 15500, 10.1073/pnas.0504114102 · DOI · Paper page
  68. Murakoshi, 2004, Single-molecule imaging analysis of ras activation in living cells, Proc. Natl. Acad. Sci. U. S. A., 101, 7317, 10.1073/pnas.0401354101 · DOI · Paper page
  69. Santos, 1988, Oligomeric structure of p21 ras proteins as determined by radiation inactivation, J. Biol. Chem., 263, 9853, 10.1016/S0021-9258(19)81595-8 · DOI
  70. Inouye, 2000, Formation of the ras dimer is essential for Raf-1 activation, J. Biol. Chem., 275, 3737, 10.1074/jbc.275.6.3737 · DOI · Paper page
  71. Tian, 2007, Plasma membrane nanoswitches generate high-fidelity ras signal transduction, Nat. Cell Biol., 9, 905, 10.1038/ncb1615 · DOI · Paper page
  72. Prior, 2003, Direct visualization of ras proteins in spatially distinct cell surface microdomains, J. Cell Biol., 160, 165, 10.1083/jcb.200209091 · DOI · Paper page
  73. Janosi, 2012, Organization, dynamics, and segregation of ras nanoclusters in membrane domains, Proc. Natl. Acad. Sci. U. S. A., 109, 8097, 10.1073/pnas.1200773109 · DOI · Paper page
  74. Janosi, 2010, Segregation of negatively charged phospholipids by the polycationic and farnesylated membrane anchor of Kras, Biophys. J ., 99, 3666, 10.1016/j.bpj.2010.10.031 · DOI
  75. Zhou, 2014, Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters, Mol. Cell. Biol., 34, 862, 10.1128/MCB.01227-13 · DOI · Paper page
  76. Kovrigina, 2015, The ras G domain lacks the intrinsic propensity to form dimers, Biophys. J ., 109, 1000, 10.1016/j.bpj.2015.07.020 · DOI
  77. Tian, 2010, Mathematical modeling of K-Ras nanocluster formation on the plasma membrane, Biophys. J ., 99, 534, 10.1016/j.bpj.2010.04.055 · DOI
  78. Freeman, 2013, The importance of Raf dimerization in cell signaling, Small GTPases, 4, 180, 10.4161/sgtp.26117 · DOI · Paper page
  79. Freeman, 2013, Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling, Mol. Cell, 49, 751, 10.1016/j.molcel.2012.12.018 · DOI · Paper page
  80. Hancock, 2003, Ras proteins: different signals from different locations, Nat. Rev. Mol. Cell Biol., 4, 373, 10.1038/nrm1105 · DOI · Paper page
  81. Cho, 2012, Raf inhibitors target ras spatiotemporal dynamics, Curr. Biol., 22, 945, 10.1016/j.cub.2012.03.067 · DOI
  82. Sha, 2017, Monobodies and other synthetic binding proteins for expanding protein science, Protein Sci., 26, 910, 10.1002/pro.3148 · DOI · Paper page
  83. Spencer-Smith, 2017, Targeting the α4-α5 interface of RAS results in multiple levels of inhibition, Small GTPases, 10.1080/21541248.2017.1333188 · DOI
  84. Gibbs, 1984, Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules, Proc. Natl. Acad. Sci. U. S. A., 81, 5704, 10.1073/pnas.81.18.5704 · DOI · Paper page
  85. Burtness, 2014, Trials, 15, 469, 10.1186/1745-6215-15-469 · DOI

Cited by

Metadata

Authors
Spencer-Smith, R., & O’Bryan, J. P.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2019-02
Volume
54
Pages
138-148
ISSN
1044-579X (ISSN-L)
OpenAlex
W2775445984
Cited by
86
References
30
FWCI
3.20
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • NIH F31 Predoctoral Award (CA192822)
  • United States (US) Department of Veterans Affairs Biomedical Laboratory Research and Development Service (1I01BX002095)
  • NIH awards (CA201717, CA212608)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.